Simulations Plus, Inc. $SLP Shares Sold by Tributary Capital Management LLC

Tributary Capital Management LLC decreased its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 7.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 361,276 shares of the technology company’s stock after selling 28,632 shares during the quarter. Tributary Capital Management LLC owned 1.79% of Simulations Plus worth $6,304,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Stephens Investment Management Group LLC acquired a new position in Simulations Plus in the 2nd quarter worth about $4,687,000. Russell Investments Group Ltd. raised its holdings in Simulations Plus by 24.9% in the 1st quarter. Russell Investments Group Ltd. now owns 223,832 shares of the technology company’s stock worth $5,488,000 after purchasing an additional 44,601 shares during the period. Comerica Bank raised its holdings in Simulations Plus by 16.6% in the 1st quarter. Comerica Bank now owns 193,990 shares of the technology company’s stock worth $4,757,000 after purchasing an additional 27,579 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Simulations Plus by 16.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 166,392 shares of the technology company’s stock worth $4,080,000 after purchasing an additional 23,139 shares during the period. Finally, Kopion Asset Management LLC raised its holdings in shares of Simulations Plus by 22.7% during the second quarter. Kopion Asset Management LLC now owns 156,401 shares of the technology company’s stock valued at $2,729,000 after acquiring an additional 28,980 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Wall Street Analyst Weigh In

SLP has been the subject of a number of research analyst reports. KeyCorp cut Simulations Plus from an “overweight” rating to a “sector weight” rating in a report on Tuesday, July 15th. Stephens reduced their target price on Simulations Plus from $28.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, July 15th. Zacks Research raised Simulations Plus to a “hold” rating in a report on Tuesday, August 12th. Cowen initiated coverage on Simulations Plus in a report on Tuesday, September 30th. They set a “hold” rating for the company. Finally, TD Cowen assumed coverage on Simulations Plus in a report on Tuesday, September 30th. They set a “hold” rating and a $16.00 target price for the company. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $24.40.

Simulations Plus Stock Performance

Shares of Simulations Plus stock opened at $17.62 on Thursday. Simulations Plus, Inc. has a one year low of $12.39 and a one year high of $37.67. The company has a market cap of $354.69 million, a price-to-earnings ratio of -5.59 and a beta of 0.99. The business’s 50 day moving average price is $14.96 and its 200 day moving average price is $20.63.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.